TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Staying Active With Arthritis: RCT of Physical Activity for Older Adults With Osteoarthritis and Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 50 years or older.~* Is community dwelling.~* Has osteoarthritis of the knee.~* Has hypertension for which monotherapy or combination pharmacological treatment is prescribed.~* Able to complete a behavioral run-in consisting of completing questionnaires, using a 7-day electronic-diary, and wearing an ActiGraph accelerometer at the waist for 7 days.~* Has written permission to participate from the physician.~Exclusion Criteria:~* Reports currently doing lower extremity exercise =\> 2 times/week.~* Reports currently fitness walking =\> 90 minutes/week.~* Incapable of managing their own treatment regimen.~* Does not have, or cannot use, a telephone or is unwilling to provide a telephone number.~* Has received cortisone or Synvisc injections in the knee, angioplasty, stents, or a pacemaker in the past 6 months.~* Reports unstable cardiovascular, pulmonary, or metabolic disease or signs and symptoms suggestive of cardiovascular, pulmonary, or metabolic disease that restrict activity.~* Has resting systolic blood pressure =\> 160 mm Hg or diastolic blood pressure =\> 100 mm Hg.~* Reports other conditions, such as osteoarthritis of the hip, spinal stenosis, inflammatory arthritis, foot drop, diabetes treated with insulin, or diabetic complications that may affect performance of lower extremity exercise and participation in fitness walking.~* Reports current knee conditions, such as meniscus tears and knee ligament ruptures.~* Reports major depression that may impact the ability to fully participate in this study.~* Is scheduled to undergo a major surgical procedure in the next 13 months.~* Is concurrently participating in a drug or psychoeducational trial that may confound, or be confounded by, participation in this study.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- STAR Intervention (Type: EXPERIMENTAL): Staying Active with Arthritis Intervention
- Attention-Control (Type: PLACEBO_COMPARATOR): Senior Health Information Intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Capecitabine Metronomic Chemotherapy to Triple-negative Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be \>=18 years of age;~* The patients must be Operable primary invasive breast cancer;~* Definitive loco-regional surgery must be completed;~* Primary tumor centrally confirmed as triple negative;~* Operable node-positive (or node-negative with tumor diameter ≥ 0.5cm);~* Chest, abdominal, bone imaging performed with 3 months prior to randomization must not reveal the presence of distant spread;~* There are normal organ function, including bone marrow function, renal function, liver function, and cardiac function;~* All patients must have signed and dated an informed consent form.~Exclusion Criteria:~* Patients with bilateral breast cancer, inflammatory carcinomas;~* Patients with positive supraclavicular or internal mammary lymph node;~* Previous breast cancer history;~* Any previous malignancy exceptions for carcinoma of the cervix, squamous carcinoma of the skin, or basal cell carcinoma of the skin;~* Pregnant or breast-feeding women;~* Women who are unwilling to agree to use an effective non-hormonal method of contraception during the treatment period of Xeloda;~* Any sex hormonal therapy;~* Malabsorption syndrome.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Capecitabine (Type: EXPERIMENTAL): Capecitabine 650 mg/m2 bid
- Standard treatment (Type: NO_INTERVENTION): Treatment according to National Comprehensive Cancer Network (NCCN) guideline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Efficacy and Safety of Insulin Detemir and NPH Insulin in Children and Adolescents With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes for at least 12 months~* Informed consent obtained~* BMI: 6-7 years: less than or equal to 19 kg/m2, 8-9 years: less than or equal to 20 kg/m2, 10-11 years: less than or equal to 22 kg/m2, 12-13 years: less than or equal to 24 kg/m2 and 14-17 years: less than or equal to 27 kg/m2.~* HbA1c equal to or less than 12.0%~Exclusion Criteria:~* Proliferate retinopathy or maculopathy~* Total daily insulin dose greater than 2.00 IU/kg~* Any condition or disease that rule out trial participation according to the judgement of the investigator.~* Mental incapacity, unwillingness or language barriers precluding understanding or cooperation.~* A life-style incompatible with trial participation

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the prostate~  * Must have one of the following prognostic factors:~    * Stage T1-2, N0; prostate-specific antigen (PSA) ≤ 10 ng/mL; and Gleason score \> 6~   * Stage T1-2, N0; PSA \> 10 ng/mL and \< 20 ng/mL; and Gleason score ≤ 6~   * Stage T3a, N0; PSA ≤ 10 ng/mL; and Gleason score ≤ 6~* Prostate volume \< 60 cc by transrectal ultrasound~* No distant or nodal metastases~  * No metastatic disease by bone scan, CT scan, or MRI~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* ECOG 0-2~Life expectancy:~* Not specified~Hematopoietic:~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~Hepatic:~* Bilirubin ≤ 1.5 times upper limit of normal~Renal:~* Not specified~Other:~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior immunotherapy for prostate cancer~Chemotherapy:~* No prior chemotherapy for prostate cancer~Endocrine therapy:~* Prior androgen-suppression therapy for up to 4 weeks duration allowed if initiated within 4 weeks of study radiotherapy~* No other prior hormonal therapy~Radiotherapy:~* No prior radiotherapy for prostate cancer~Surgery:~* No prior surgery for prostate cancer~* No prior transurethral resection of the prostate~Other:~* No prior alternative therapy (e.g., PC-SPES) for prostate cancer

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Androgen suppression + EBRT + Brachytherapy (Type: EXPERIMENTAL): Androgen suppression with external beam radiation therapy followed by brachytherapy boost

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Pathologically diagnosed glioblastoma multiforme or other malignant glioma~  * Recurrent disease~* Must have received prior temozolomide~PATIENT CHARACTERISTICS:~* Karnofsky performance status 60-100%~* Granulocyte count ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* SGOT ≤ 2.5 times upper limit of normal (ULN)~* Creatinine ≤ 2 times ULN~* Bilirubin ≤ 2 times ULN~* No other active malignancy except for cervical carcinoma in situ or basal cell carcinoma of the skin~* No serious medical or psychiatric illness that, in the opinion of the investigator, would preclude study treatment~* No medical condition that precludes swallowing pills~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Recovered from all prior therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Temozolomide (Type: EXPERIMENTAL): Following diagnosis of tumor recurrence or progression, all patients will receive of daily low dose temozolomide given at 50mg/m2/d without interruption. Brain imaging will be performed at baseline and every 2 months (standard of care). The treatment will be administered until development of toxicity, evidence of progression of disease or death.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A practicing urologist at an intervention site, OR~* A member of the antimicrobial stewardship team at an intervention site~Exclusion Criteria: None

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intervention (Type: EXPERIMENTAL): We will randomly select 3 intervention sites from the top quartile of all VHA sites, as ranked by the frequency of excessive post-procedural antimicrobial use after the 3 urologic procedures of interest. We will provide feedback both at baseline and at regular intervals to the 3 intervention sites. Data on hospital-level excessive post-procedural antimicrobial use specific to urologic patients (primary outcome) will be shared at baseline with the intervention sites. Updated data will be sent electronically to urology providers and the antimicrobial stewardship team at the intervention site every other month via electronic mail. These data will include an anonymous comparison to all other VHA hospitals.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 years or older.~2. Patients with an Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.~3. Histologically confirmed metastatic or local recurrence of breast cancer.~4. ER positive and/or progesterone receptor (PR) positive, HER-2+ defined as immuno-histochemistry3+ staining or FISH+.~5. Prior adjuvant Trastuzumab therapy is permitted, but disease-free interval (DFI) must be more than 12 months.~6. Patients must have measurable or evaluable disease.~7. Adequate bone marrow reserve with neutrophils \> 1000 and platelets \> 100,000.~8. Adequate renal function with serum creatinine \< 2.0.~9. Adequate hepatic reserve with serum bilirubin \< 2.0, alanine transaminase(ALT) \< 3 times the upper limit of normal, and alkaline phosphatase \< 5 times the upper limit of normal.~10. Adequate cardiac reserve with at least 45% of Left ventricular ejection fraction (LVEF) by echocardiogram.~11. Able to give informed consent.~12. Life expectancy of at least 12 weeks.~Exclusion Criteria:~1. Pregnant or breast feeding.~2. ECOG score ≧2~3. DFI \<12 months.~4. LVEF \< 45% by echocardiogram.~5. Uncontrolled medical problems.~6. Evidence of active acute or chronic infection.~7. Hepatic, renal, or bone marrow dysfunction as detailed above.~8. Concurrent malignancy or history of other malignancy within the last five years except as noted above.~9. Known severe hypersensitivity to Trastuzumab.~10. Patients were unable or unwilling to comply with program requirements.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Palliative chemotherapy (Type: ACTIVE_COMPARATOR): Chemotherapy combined with trastuzumab. Chemotherapy could use the following drugs such as capecitabine , Vinorelbine, or Gemcitabine.
- Palliative endocrine therapy (Type: EXPERIMENTAL): Endocrine therapy combined with trastuzumab. Endocrine therapy could use tamoxifen or aromatase inhibitors including anastrozole, letrozole, or exemestane.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Active arthritis at screening/baseline as indicated by \>/= 3 tender/painful and 3 swollen joints~* Active plaque psoriasis at screening~* Inadequate efficacy or lack of toleration to previously administered TNF inhibitor~Exclusion Criteria:~* Non-plaque forms of psoriasis (with exception of nail psoriasis)~* History of autoimmune rheumatic disease other than PsA; also prior history of or current, rheumatic inflammatory disease other than PsA

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Sequence A (Type: EXPERIMENTAL): Tofacitinib 5 mg BID for 6 months
- Treatment Sequence B (Type: EXPERIMENTAL): Tofacitinib 10 mg BID for 6 months
- Treatment Sequence C (Type: PLACEBO_COMPARATOR): Placebo for 3 months then tofacitinib 5 mg BID for 3 months
- Treatment Sequence D (Type: PLACEBO_COMPARATOR): Placebo for 3 months then tofacitinib 10 mg BID for 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must have had a diagnosis of active JIA (polyarticular, extended oligoarticular, or enthesitis-related juvenile idiopathic arthritis \[ERA\] including JPsA).~* Participants must have had an inadequate response to at least one conventional or biologic disease-modifying antirheumatic drug (DMARD).~Exclusion Criteria:~* Participants must not have systemic JIA, with or without active systemic features.~* Participants must not have persistent oligoarticular arthritis.~* Participants must not have been previously treated with a Janus kinase (JAK) inhibitor.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Baricitinib (Type: EXPERIMENTAL): Baricitinib was administered QD (once daily) as a 4-mg oral tablet for adolescent participants (12 to \<18 years of age) and children ≥9 years of age; and 2 mg for children \<9 years of age. Participants \<6 years of age received an oral suspension. Participants ≥6 to \<12 years old had the option of receiving an oral suspension. Participants \>12 years old were supplied tablets. The oral suspension dose was administered as 4-mg, 2-mg, 1-mg, and 0.5-mg as needed.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matched to baricitinib was administered to participants during the DBW period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficiency Of The Methotrexate At Patients Affected By Grave Pelade

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. - age 18 to 70 years old~2. - informed consent,~3. - severe type of AA defined as : 3.1 - AA totalis universalis 3.2 - evolving for more than 6 months despite previous treatments including photothérapy (PUVA oru UVB), applications of super potent topical corticosteroid ( clobetasol propionate), applications of minoxidil 5%, or IV pulse corticosteroids 3.3 - DLQI score superior or equal to 10~Exclusion Criteria:~* Pregnant or breast feeding women~* VIH + patients~* active hepatitis B or C~* treatment with immunosuppressant (ciclosporine, mycophénolate mofetil~  , cyclophosphamide, azathioprine, méthotrexate) within 2 months before inclusion~* severe cardiac arythma or severe cardiac insufficiency or severe coronary disease~* liver disorder~* alcool consumption~* renal failure~* Severe diabetes mellitus~* past history of severe infection~* past history of néoplasiae ( excluding BCC),~* Karnofsky index \<à 50 %~* severe lung disorder~* mental impairment~* symptomatic osteoporosis~* blood cytopénia (hémoglobine \< 10 g/l ; leucocytes\< 3000/mm3, platelets\< 100 000/mm3)~* albuminémia \< 25 g/l

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ARM A : METHOTREXATE (Type: PLACEBO_COMPARATOR): Arm A: methotrexate 20 to 25 mg / week for 6 months. Patients who will experience at least a 25% hair regrowth after the month 5 evaluation will continue methotrexate or placebo from month 6 to the end of the study (month 12).~Non responder patients in both arms A and B will be re-randomized to receive from month 6 to the end of the study (month 12):~* methotrexate alone or~* methotrexate associated with prednisone 0.3 mg/Kg/day
- ARM B : PLACEBO (Type: PLACEBO_COMPARATOR): Arm B placebo Patients who will experience at least a 25% hair regrowth after the month 5 evaluation will continue methotrexate or placebo from month 6 to the end of the study (month 12).~Non responder patients in both arms A and B will be re-randomized to receive from month 6 to the end of the study (month 12):~* methotrexate alone or~* methotrexate associated with prednisone 0.3 mg/Kg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Scleroderma Lung Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with limited or diffuse systemic scleroderma if they had evidence of active alveolitis on examination of bronchoalveolar-lavage (BAL) fluid (defined as neutrophilia of ≥3 percent, eosinophilia of ≥2 percent, or both)on thoracic high-resolution computed tomography (CT), any ground-glass opacity,~2. Onset of the first symptom of scleroderma other than Raynaud's phenomenon within the previous seven years,~3. An FVC between 45 and 85 percent of the predicted value~4. Grade 2 exertional dyspnea according to the baseline instrument of the Mahler Dyspnea Index (as measured with the use of the magnitude-of-task component).~Exclusion Criteria:~1. A single-breath carbon monoxide diffusing capacity (DlCO) that was less than 30 percent of the predicted value,~2. A history of smoking within the preceding six months, other clinically significant pulmonary abnormalities,~3. Clinically significant pulmonary hypertension requiring drug therapy.~4. Patients taking prednisone at a dose of more than 10 mg per day, those who had previously been treated for more than four weeks with oral cyclophosphamide or had received two or more intravenous doses,~5. Patients who recently received other potentially disease-modifying medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cylophosphamide (Type: EXPERIMENTAL): Cyclophosphamide (Cytoxan, Bristol-Myers Squibb) was initiated with a dose of 1 mg per kilogram of body weight per day (to the nearest 25 mg). The doses were increased monthly by one capsule up to 2 mg per kilogram.
- Placebo (Type: PLACEBO_COMPARATOR): Matching gel caps at a dose of 25 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete